gms | German Medical Science

33. Internationale Konferenz für Elektrokardiographie

Internationale Konferenz für Elektrokardiographie

Amiodarone in complex life threatening dysrhythmias in children

Meeting Abstract

  • author J. Keller - KKSK, Pediatric Cardiology, University of Cologne, Cologne, Germany
  • corresponding author presenting/speaker B. Roth - KKSK, Pediatric Cardiology, University of Cologne, Cologne, Germany
  • author M. Emmel - KKSK, Pediatric Cardiology, University of Cologne, Cologne, Germany
  • N. Sreeram - KKSK, Pediatric Cardiology, University of Cologne, Cologne, Germany
  • author K. Brockmeier - KKSK, Pediatric Cardiology, University of Cologne, Cologne, Germany

33rd International Congress on Electrocardiology. Cologne, 28.06.-01.07.2006. Düsseldorf, Köln: German Medical Science; 2007. Doc06ice148

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 8. Februar 2007

© 2007 Keller et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Amiodarone is a potent substance to successfully suppress episodes of tachycardia, syncope or sudden cardiac death. In the treatment of dysrhythmias in the elderly amiodarone is used for decades and is increasingly prescribed for patients with ventricular and supraventricular tachyarrhythmias. However, amiodarone treatment carries a risk of potentially serious pulmonary, cardiac, hepatic, thyroid, ocular, peripheral neurological and cutaneous (photosensitivity) adverse effects. The average plasma elimination half-life of amiodarone is about 50 days. Life threatening dysrhythmias do also occur in the peadiatric age group. A possible treatment is amiodarone medication as a last choice option. Meanwhile cardiologists, pharmacologists and others expect similar potential adverse effects in children during the course of the treatment with amiodarone, pediatric cardiologist’s viewpoint is that adverse effects in children are rare within the typical precription doses in successful treatment. However, there is no study available proving a different behavior of amiodarone in children. A multi centre serial observation study on amiodarone in children is planed using the networking facilities of the Cologne Centre for Clinical Studies, which is actually performing the first randomized double blind multi centre study on pharmacologic treatment in children, the clonidine study. Study design is a prospective observation of amiodarone treatment in a subset of more than 20 centres caring for dysrhythmias in childhood. Indication for amiodarone as a last choice drug is irresponsiveness to treatment with common antiarrhythmic drugs in the care of patients with life threatening tachycardias. Inclusion criteria, effect of treatment as well as potential adverse effects will be documented in a data base. After a five year interval the hypothesis of whether or not side effects occur less in children will be evaluated.